Ochsner Baton Rouge welcomed several new providers, including Dr. Emilio Fabian Corona, a pulmonology and critical care medicine specialist who has joined Ochsner Health Center – Prairieville.

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

This Cochrane review does not find that vitamin D offers protection against acute flare-ups of chronic obstructive pulmonary disease (COPD), a chronic, inflammatory lung disease that causes breathing ...

Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with ...

The Immunology of Obstructive Lung Disease and Emergence of Biologic Treatment This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi, and ...

Chronic obstructive pulmonary disease (COPD) ranks third globally in terms of cause of death, after heart disease and cancer. Persistent lung conditions that obstruct airflow from the lungs can lead ...

Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and ...

Among sarcoidosis third-line therapies, infliximab has proved modestly effective and efzofitimod shows promise for pulmonary disease, while tofacitinib and adalimumab may hold promise for treating ...

Add a description, image, and links to the lung-disease-detection topic page so that developers can more easily learn about it ...

About the American Lung Association The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and ...

Introduction Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disorder characterized by persistent inflammation, airway remodeling, and immune activation in the lung parenchyma.

A raised blood eosinophil count (≥300 cells per μL), a marker of type 2 inflammation, can identify patients with chronic obstructive pulmonary disease (COPD) with higher exacerbation risk. Dupilumab ...